Thematics Asset Management Boosts Holdings in DexCom, Inc. $DXCM

Thematics Asset Management increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 7.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 337,686 shares of the medical device company’s stock after acquiring an additional 22,294 shares during the quarter. DexCom comprises approximately 1.3% of Thematics Asset Management’s portfolio, making the stock its 18th largest holding. Thematics Asset Management owned about 0.09% of DexCom worth $29,477,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Andra AP fonden acquired a new stake in shares of DexCom during the second quarter worth about $26,000. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of DexCom in the 2nd quarter valued at about $26,000. Zions Bancorporation National Association UT purchased a new position in DexCom during the 1st quarter worth approximately $27,000. Anderson Financial Strategies LLC purchased a new position in DexCom during the 1st quarter worth approximately $37,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom during the second quarter worth approximately $45,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DXCM. Sanford C. Bernstein reissued an “outperform” rating and issued a $84.00 price objective on shares of DexCom in a report on Monday, November 3rd. JPMorgan Chase & Co. reduced their price target on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating for the company in a research report on Friday, October 31st. Wall Street Zen cut shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 16th. Royal Bank Of Canada lowered their price objective on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a research report on Friday, October 31st. Finally, UBS Group dropped their price objective on shares of DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, November 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $87.27.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $65.49 on Monday. The stock has a fifty day moving average price of $63.97 and a 200 day moving average price of $75.00. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. The company has a market cap of $25.54 billion, a PE ratio of 36.38, a P/E/G ratio of 1.40 and a beta of 1.51.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The company had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same quarter in the prior year, the firm earned $0.45 EPS. DexCom’s quarterly revenue was up 21.6% on a year-over-year basis. Sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling

In other news, COO Jacob Steven Leach acquired 18,200 shares of DexCom stock in a transaction that occurred on Monday, November 10th. The stock was purchased at an average price of $55.04 per share, for a total transaction of $1,001,728.00. Following the completion of the transaction, the chief operating officer directly owned 331,697 shares in the company, valued at approximately $18,256,602.88. This trade represents a 5.81% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total value of $58,766.84. Following the completion of the sale, the director directly owned 27,031 shares in the company, valued at $1,569,690.17. This represents a 3.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 7,866 shares of company stock valued at $448,177 over the last ninety days. Corporate insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.